SpyGlass Pharma, Inc. director Kirk G. Nielsen filed a Form 4 on November 18, 2026, reporting three transactions in common stock on November 16, 2026, all coded as "J" and all at a price of $0.00, related to pro-rata in-kind distributions among affiliated Vensana Capital entities.
Key Highlights
- Reporting person: Kirk G. Nielsen, director of SpyGlass Pharma, Inc. (NASDAQ:SGP).
- Transaction date: All three transactions occurred on November 16, 2026, each with a transaction code of "J" and a price of $0.00.
- First transaction: 331,036 shares disposed of (D) by Vensana Capital I, L.P. via pro-rata distribution to its partners, leaving 2,979,583 shares held indirectly by that entity.
- Second transaction: 8,646 shares acquired (A) by Vensana Capital I GP, LLC ("Vensana GP I") as a result of the same in-kind distribution, bringing that entity's indirect holding to 8,646 shares.
- Third transaction: 8,634 shares disposed of (D) by Vensana GP I via pro-rata distribution to its members, leaving 12 shares held indirectly by Vensana GP I.
- Beneficial ownership disclaimed: According to the filing, Vensana GP I and each of the GP I Managing Directors "disclaims beneficial ownership of these securities," except to the extent of their respective pecuniary interests.
Pro-Rata In-Kind Distributions Among Vensana Capital Entities
According to the filing, the three reported transactions reflect a reorganization of share ownership within affiliated Vensana Capital entities rather than open-market purchases or sales. The first transaction shows Vensana Capital I, L.P. distributing 331,036 shares of SpyGlass Pharma common stock on a pro-rata basis to its partners for no additional consideration. Following that distribution, Vensana Capital I, L.P. retained 2,979,583 shares held indirectly by Nielsen as a result of his role as a managing director of Vensana Capital I GP, LLC, the general partner of Vensana Capital I, L.P.
The second and third transactions capture the corresponding movement at the general partner level. Vensana GP I received 8,646 shares from the in-kind distribution by Vensana Capital I, L.P., representing a change in the form of ownership rather than a new acquisition of shares. Vensana GP I then distributed 8,634 of those shares to its own members on a pro-rata basis, again for no consideration, leaving a residual holding of 12 shares. The filing states that each of the GP I Managing Directors, which include Nielsen and Peter Justin Klein, may be deemed to share voting, investment, and dispositive power over shares held by Vensana GP I by virtue of their roles as managing directors of that entity.
The filing was signed by Steven Schwen as attorney-in-fact for Kirk Nielsen on November 18, 2026. All three transactions carried transaction code "J," consistent with the filing's characterization of them as distribution events and not purchases or sales.
What Was Disclosed
Kirk G. Nielsen, a director of SpyGlass Pharma, Inc. (NASDAQ:SGP), reported three code "J" transactions on November 16, 2026, reflecting pro-rata in-kind distributions of common stock among Vensana Capital entities at $0.00 per share, with beneficial ownership disclaimed except as to pecuniary interest.



Please wait processing your request...